Navigation Links
Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study

ve GIST. In a statement issued today by the NIH, the new findings were heralded as excellent news, with major implications for patients with primary disease.

"With these new data, we see that Glivec may help patients with early GIST," said Diane Young, MD, Head of Global Medical Affairs at Novartis Oncology. "We will now work with the investigators on a submission to gain regulatory approval for Glivec as adjuvant treatment for GIST."

Following the recommendation of a data monitoring committee, the study will be closed and patients in the study who are currently being treated with placebo may choose to receive one year of Glivec.

In the study, patients were randomized to one of two treatment arms. Neither the patients nor physicians knew which treatment the patients were receiving. One patient group received Glivec at a dose of 400 mg per day for one year, while the second group received placebo for one year. According to the study design, patients who developed a recurrence of their cancer while on a study therapy were unblinded to their treatment assignment. Those receiving placebo subsequently received Glivec, while those already given Glivec continued with this therapy but at a higher dose. Study results will be presented at a forthcoming scientific meeting.

Gastrointestinal stromal tumors (GIST) belong to a group of cancers known as soft tissue sarcomas that usually arise from the intestinal tract, with the most common site being the stomach and followed by the small intestine. The incidence of GIST is estimated to be 4,500-6,000 new cases per year in the US (15-20 cases per million population), of which more than 90% are Kit-positive.

Investigators in the NCI study reported that Glivec therapy was well tolerated by most patients, with side effects similar to those observed in other clinical trials with Glivec. These include nausea, diarrhea and swelling (edema). Information on more than 600 patients enrolled in the study was
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

Post Your Comments:
(Date:11/6/2009)...Newswire-FirstCall/ -- Recession in domestic and i...r Allied Healthcare Products in the first quarter ..., Sales declines pushed Allied into a loss for th... $745,000, or negative 9 cents per share, compared...0, or 3 cents per share. ,, Sales fell about 2...
(Date:11/6/2009)...Newswire/ -- Trius Therapeutics, Inc. announced to...Form S-1 with the U.S. Securities and Exchange Com...c offering of shares of its common stock. All shar...will be offered by the Company. ,, Credit Suiss...ing manager, Piper Jaffray & Co. is acting as ...
(Date:11/6/2009)...6 Repossessions and liquidations o...d quarter of 2009 declined as compared to similar ...ement,s NasTrac Quarterly Index (NQI). The figure...both repossessions and orderly liquidations, also ...ction and printing equipment, offering mixed news ...
Breaking Medicine Technology:Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 1LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 2LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 3LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 4SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 1SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 2SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 3SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 4SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS 13331 5PDL BioPharma Elects Barry Selick to Its Board of Directors 53479 1PDL BioPharma Elects Barry Selick to Its Board of Directors 53479 2
... New product recently approved by FDA for long-ter...n; data demonstrate,first nebulized formoterol fum...o dry powder formoterol, enhanced patient quality ... (May 20, 2007) – Data presented at the,Inte...ety (ATS),demonstrate that Perforomist™ (for...
...BRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2007 - Glo... biopharmaceutical,company, announced today that t...nted Fast Track designation for its novel histone,...rapy of,previously treated peripheral T-cell lymph...hat it has reached an agreement with the,FDA under...
Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma 2Gloucester Pharmaceuticals Receives Fast Track Designation for,Romidepsin in Peripheral T-Cell Lymphoma 3
(Date:11/8/2009)...tions is pleased to announce that it has been succ... ReSound who recently received an award on the $80...rd includes not only the Veterans Administration, ...al agencies. , New York, ... is pleased to announce that it has been successfu...
(Date:11/8/2009)...ewswire/ -- Today, the House of Representatives pa... Ellsworth and Lipinski amendment to the "Affordab...mendment maintains the current policy of preventin...ckages that include abortion. It clarifies that in...edits and those who do not, can with their own fun...
(Date:11/8/2009)...ewswire/ -- Pharmaceutical Research and Manufactur...ohnson released the following statement regarding ...isappointed, but not surprised by today,s vote -- ...ericans as well as nearly half of the members of t... the bill. ,, "While well intentioned, the bill...
(Date:11/8/2009)...With Working Families vs. Insurance Companies ,... -- On the heels of an historic late night vote in... health care reform bill, the Pennsylvania AFL-CIO...esentatives voted on HR 3962, the Affordable Healt...ich passed Saturday evening by a vote of 220 to 21...
(Date:11/7/2009)...USNewswire/ -- Speaker Nancy Pelosi spoke on the ...ordable Health Care for America Act. The House wi...re the Speaker,s remarks. ,, "Madam Speaker, t...r nation and for American families. For nearly a ...osophy -- as far back as Teddy Roosevelt -- have c...
Breaking Medicine News(10 mins):Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4
...ll "Laugh for a Week and Learn for a Lifetime", M...ohnson company and the maker of OneTouch(R) Blood ...nced an online sweepstakes that will offer,an oppo...s available at http://www.DiabetesAndKids.com an...
...ught gray hair, says Chicago father of 3 who has ..., April 11 (HealthDay News) -- Construction forema... started to go. He,d forget things: his schedule, ...or the doctor,s verdict. , "When they said Jim had...
...quency ablation in the treatment of colorectal liv...w recurrence rate, according to a recent study con...ranklin in Berlin, Germany. , Radiofrequency abl... is not an option. However, because of limited siz...
...for EMRs Best Meeting Medicolegal Requirements, B...ectronic health records systems remain in active d...ple organizations including ASTM, HL7, and,HITSP. ...ere are few resources for those who do take the ti...
...raeger was awarded with the,2007 Frost & Sullivan ...ard,goes to honor the manufacturer which best fulf... concerning the aspects of safety, ease of use,tec...m Frost & Sullivan,concerning Personal Protective ...
...e in differentiating the blood supply to medial an...atment planning and prognosis according to a study...mi in Miami, FL and the Rabin Medical Center in Pe...nternal or lateral mammary branches. , MRI is cu...
Other Medicine News:Health News:OneTouch(R) Laugh & Learn Sweepstakes to Award Scholarships for Summer Camp Experiences to Children with Diabetes 2Health News:OneTouch(R) Laugh & Learn Sweepstakes to Award Scholarships for Summer Camp Experiences to Children with Diabetes 3Health News:When a Mind Begins to Disappear: A Young Family's Journey to the Dark Side 2Health News:When a Mind Begins to Disappear: A Young Family's Journey to the Dark Side 3Health News:When a Mind Begins to Disappear: A Young Family's Journey to the Dark Side 4Health News:When a Mind Begins to Disappear: A Young Family's Journey to the Dark Side 5Health News:Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements 2Health News:Draeger Receives Frost & Sullivan Consumer Award for Respiratory Protection 2
Dodick-Kammann Nucleus Chopper
Chang Phaco Chopper
Denman Brown Nucleus Cracker
Forceps Epilation Angled End B510.10 3.5"
Medicine Products: